We're QuBind, and we accelerate the bench-to-bedside timeline for T-cell receptor immunotherapy. We're a startup designed to enable next generation immunotherapeutics by solving the three major current challenges in T-cell immunotherapy: long and expensive discovery processes, unpredictable side effects, and outdated patient stratification for clinical trials.
At ONE MILLIONTH of the cost and time invested per novel therapy, we can generate T-cell receptors similar to highly validated clinical patents. Thanks to our deep domain knowledge and sophisticated data science team, we are able to disentangle complex immunological mechanisms and mimic evolutionary pressure to optimize T-cell binding affinity for any given cancer type.
As a one-stop-shop SaaS suite, we offer services for T-cell screening, safety, and discovery. We can optimize clinical trials, screen effective therapies from customer databases, and minimize off-target effects. Our platform is comprised of flexible dockerized microservices running in parallel that are designed to scale for a large customer base. We also offer our customers a unique success-based partnership program for the discovery of novel therapies, wherein we work together to achieve validation milestones necessary before FDA clinical trials.
Company Details
- Address
- Boston, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- for T-cell screening.
- HQ
- Boston
Qubind (Acquired) Questions
Qubind (Acquired)'s LinkedIn profile is https://www.linkedin.com/company/qubind
Qubind (Acquired)'s industry is
Biotechnology Research
Qubind (Acquired)'s top competitors are
Cellergy Therapeutics,
4immune Therapeutics,
Rnaway,
Virucure Therapeutics,
Lepton Pharmaceuticals,
Immunotherapy Research Center,
Crispr Stem & Therapeutics Ltd.,
Onecell Medical Ltd,
Stemcellerant,
Cg - Cell Generation.
Qubind (Acquired)'s categories are Biotechnology Research
